Furthermore, compared to conventional clinical imaging evaluation on tumor mass, positively detected post‐therapeutic EpCAM+ CTECs and CTCs, particularly de novo EpCAM+/Vim+ E/M‐type CTECs, may be indicative biomarkers in terms of timely indexing therapeutic efficacy and detecting emerging resistance to treatment. The gene discussed is EPCAM; the disease is neoplasm.